1h Free Analyst Time
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation. This receptor also plays an important role in trafficking of dendritic cells. The CC chemokines CCL3, CCL5, CCL17 and CCL22 signal through this receptor. Speak directly to the analyst to clarify any post sales queries you may have.
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Ophthalmology, Respiratory and Undisclosed which include indications Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Melanoma, Non-Hodgkin Lymphoma, Adenocarcinoma Of The Gastroesophageal Junction, Allergic Asthma, Allergic Conjunctivitis, Atopic Dermatitis (Atopic Eczema), Cervical Cancer, Chronic Urticaria Or Hives, Colon Tumor, Eosinophilic Esophagitis, Esophageal Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Liver Cancer, Nasopharyngeal Cancer, Non-Small Cell Lung Cancer, Pancreatic Tumor, Rhinosinusitis, Solid Tumor, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC) and Unspecified.
The latest report C-C Chemokine Receptor Type 4 - Drugs In Development, 2022, outlays comprehensive information on the C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)
- The report reviews C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- REPORT COVERAGE
- C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Overview
- C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Companies Involved in Therapeutics Development
- ChemoCentryx Inc
- CohBar Inc
- Eight Plus One Pharmaceutical Co Ltd
- Lassogen Inc
- RAPT Therapeutics Inc
- Tizona Therapeutics Inc
- C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Drug Profiles
- BJY-809 - Drug Profile
- Product Description
- Mechanism Of Action
- CB-5046 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CCX-6239 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- FLX-475 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Gene Therapy to Target CD30 and CCR4 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LAS-20X - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibody to Target CCR4 for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RPT-193 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Dormant Products
- C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Discontinued Products
- C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Product Development Milestones
- Featured News & Press Releases
- May 23, 2022: RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis
- Mar 28, 2022: RAPT Therapeutics announces biomarker data from phase 1b trial of RPT193 consistent with disease modification in atopic dermatitis
- Oct 18, 2021: RAPT Therapeutics announces upcoming oral presentation of RPT193 phase 1b data at the 4th Inflammatory Skin Disease Summit
- Sep 30, 2021: RAPT Therapeutics announces late-breaking oral presentation of positive results from phase 1b trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress
- Sep 20, 2021: RAPT Therapeutics to present RPT193 phase 1b data at 30th European Academy of Dermatology and Venereology Congress
- Jun 14, 2021: RAPT Therapeutics reports positive topline results from phase 1b trial of RPT193 monotherapy in atopic dermatitis
- Jun 13, 2021: RAPT Therapeutics to report top line data from phase 1b trial of RPT193 in atopic dermatitis
- Mar 22, 2021: Rapt Therapeutics completes enrollment in phase 1b trial of RPT193 in atopic dermatitis
- Nov 16, 2020: RAPT Therapeutics reports positive initial data from ongoing phase 1/2 clinical trial of FLX475 in multiple cancer indications
- Nov 15, 2020: RAPT Therapeutics to announce initial data from phase 1/2 clinical trial of FLX475 in multiple cancer indications
- May 15, 2020: RAPT Therapeutics highlights early results for RPT193 at Society for Investigative Dermatology Meeting
- Oct 23, 2019: RAPT Therapeutics announces initiation of first-in-human phase 1 study of RPT193
- Jul 08, 2019: RAPT Therapeutics announces the appointment of Emma Guttman-Yassky, M.D., Ph.D., a leading expert in the field of inflammatory skin diseases, to its scientific advisory board
- May 13, 2019: FLX Bio highlights preclinical atopic dermatitis and asthma data for FLX193 at the American Association of Immunologists (AAI) Annual Meeting 2019
- Nov 29, 2018: ChemoCentryx announces presentation on novel small molecule inhibitor CCX6239 at American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by ChemoCentryx Inc, 2022
- Pipeline by CohBar Inc, 2022
- Pipeline by Eight Plus One Pharmaceutical Co Ltd, 2022
- Pipeline by Lassogen Inc, 2022
- Pipeline by RAPT Therapeutics Inc, 2022
- Pipeline by Tizona Therapeutics Inc, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ChemoCentryx Inc
- CohBar Inc
- Eight Plus One Pharmaceutical Co Ltd
- Lassogen Inc
- RAPT Therapeutics Inc
- Tizona Therapeutics Inc
